Electronic tool for argumentation and evidence sharing: For a global pharmaceutical company, CRA developed an electronic toolkit that presented evidence and arguments on a range of policy challenges and incorporated evidence of the company’s economic footprint.
Regional policy development: Consistency of arguments across countries and regions is becoming increasingly important. A global pharmaceutical company asked CRA to work with local affiliates to develop regional policy positions that were sustainable over the medium term.
Thematic evidence base development: Different countries often face similar challenges. Following the financial crisis, a global pharmaceutical company asked CRA to analyse the health care market across multiple countries and create a toolkit that demonstrated and quantified thematic evidence of potential inefficiencies.
CRA's RADAR Insights: Impact of US pricing strategies on orphan drug pricing in Germany - Part 3
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...